• Current management of adults with chronic plaque psoriasis includes topical agents such as corticosteroids; traditional systemic therapy such as methotrexate, acitretin, or cyclosporine; and biological agents (e.g., tumour necrosis factor inhibitors, an interleukin-12/23 inhibitor, and an interleukin-17 inhibitor).
• Apremilast is an orally administered, small-molecule phosphodiesterase 4 inhibitor. It has a novel mechanism of action, targeting multiple steps in the pathogenesis of psoriasis. The marketing authorisation from the European Medicines Agency for the use of apremilast in patients with psoriasis and psoriatic arthritis was granted on January 15, 2015.
• Apremilast is indicated in patients with moderate to severe, chronic plaque psoriasis who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate, or psoralen and ultraviolet-A light (PUVA).
OBJECTIVE
• This cost-utility analysis was developed to assess the value for money of apremilast in the Italian setting for patients with moderate to severe, chronic plaque psoriasis (defined as Psoriasis Area and Severity Index [PASI] score ≥10).
METHODS
• A Markov state-transition cohort model was adapted to the Italian setting to compare costs and quality-adjusted life-years (QALYs) from 2 treatment sequences ( Figure 1 ):
-Apremilast, etanercept, adalimumab, ustekinumab, and best supportive care (BSC).
-Etanercept, adalimumab, ustekinumab, and BSC.
• The time horizon of the analysis was 5 years, and the perspective adopted was that of the Italian National Health Service (NHS). The cycle length was 28 days. • Patients in the intervention (apremilast) arm entered the model receiving a trial of apremilast (trial period) and proceeded to a continued-use period if they achieved a response to treatment at the end of the trial period. Patients who did not achieve a response at the end of the trial period proceeded to the trial period of the next treatment. During the continued-use phase of any treatment, patients continued treatment until they withdrew due to loss of efficacy or other causes. The same process occurred in the comparator arm, but patients started with a biological therapy (etanercept).
• Response to treatment in the model is based on the probability of achieving a ≥75% improvement in PASI score (PASI-75) in each model cycle.
• Given the lack of head-to-head studies, response rates for apremilast and biological therapies were obtained from a network meta-analysis that included 22 randomised controlled trials published between 2001 and 2013 ( Table 1) . • Utility weights associated with PASI states were taken from a UK NHS health technology assessment appraisal, given the lack of Italian data.
2
• Unit costs were generally taken from Italian standard sources for biological therapy acquisition costs, physician visits, screening, and monitoring tests (e.g.,Gazzetta Ufficiale regional tariffs, Farmadati database). 3, 4 Given that apremilast is not currently reimbursed by the Italian NHS, the cost of apremilast 30 mg BID was set at the UK NHS publicly available price. 5 • Frequency of screening and monitoring was obtained from real-world data (administrative database analysis performed by Clicon S.r.l.
[data on file]).
• Key model parameters, assumptions, and sources are presented in Table 2 and Table 3 .
• Best supportive care was assumed as use of traditional systemic therapies (cyclosporine or methotrexate). • Deterministic sensitivity analyses on several model parameters, including changing efficacy data, utility weights, or discount rates, showed that the apremilast sequence remained dominant in almost all cases, and cost-saving in the remaining analyses ( Table 5 ). • Base case results were instead very sensitive to changes in the time horizon of the analysis. For example, with a longer time horizon, the apremilast sequence led to higher incremental QALYs (0.07) but was not less expensive, leading to an incremental cost of €2,568 and to an incremental cost-effectiveness ratio of €35,239.
• The probabilistic sensitivity analysis corroborated the findings of the base case and showed that apremilast was dominant in approximately 60% of simulations and dominant or cost-saving in 99.5% of simulations ( Figure 2) . 
CONCLUSION
• This analysis suggests that the use of apremilast for treatment of moderate to severe psoriasis may represent a cost-saving option for the Italian NHS without any loss in patient quality of life.
